Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-03-2019 | Review

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Authors: Jesús Troya, Pablo Ryan, Rocío Montejano, Alfonso Cabello, Guillermo Cuevas, Mariano Matarranz, Irene Cañamares, Javier Solís, Luis Álvarez-Sala Walther

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2019

Abstract

Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.

European Guidelines for treatment of HIV-infected adults in Europe. Guidelines version 9.0. European AIDS Clinical Society (EACS), October, 2017. Available at: http://www.eacsociety.org/files/guidelines_9.0-english.pdf. (Accessed August 2018)

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services USA. Available at: https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.pdf. (Accessed August 2018)

Raltegravir (Edurant®). Data sheet available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdf (Accessed August 2018)

Rilpivirine (Issentress®). Data sheet available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022145s004lbl.pdf (Accessed August 2018)

Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Ostergaard L, Langdahl BL, Laursen AL (2012) Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 7(3):e32445. https://doi.org/10.1371/journal.pone.0032445 CrossRefPubMedPubMedCentral

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, ASSERT Study Group (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51:963–972. https://doi.org/10.1086/656417 CrossRefPubMed

Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P, Martinez E, Ryan P, Górgolas M, Podzamczer D, Knobel H, Gutiérrez F, Ribera E (2016) Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother 71(12):3510–3514. https://doi.org/10.1086/656417 CrossRefPubMed

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S, extended SPRING-2 Study Group (2013) Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13(11):927–935. https://doi.org/10.1016/S1473-3099(13)70257-3 CrossRefPubMed

Troya J, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terrón JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solís J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A (2016) Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study. PLoS One 11(10):e0164455. https://doi.org/10.1371/journal.pone.0164455 CrossRefPubMedPubMedCentral

10.

Palacios R, Pérez-Hernández IA, Martínez MA, Mayorga ML, González-Domenech CM, Omar M, Olalla J, Romero A, Romero JM, Pérez-Camacho I, Hernández-Quero J, Santos J (2016) Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis 35(5):815–819. https://doi.org/10.1007/s10096-016-2602-3 CrossRefPubMed

11.

Marshall N, Hedley L, Smith C, Swaden L, Tsintas R, Edwards S, Waters L, Johnson M (2014) Is switching to Kivexa with rilpivirine as effective as switching to Eviplera in clinical practice? HIV Med 17(Suppl. 1):19. https://doi.org/10.1111/hiv.12393 CrossRef

12.

Galizzi N, Galli L, Poli A, Gianotti N, Carini E, Bigoloni A, Tambussi G, Nozza S, Lazzarin A, Castagna A, Mancusi D, Termini R (2018) Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLoS One 13(2):e0191300. https://doi.org/10.1371/journal.pone.0191300 CrossRefPubMedPubMedCentral

13.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24(11):1697–1707. https://doi.org/10.1097/QAD.0b013e32833a608a CrossRefPubMed

14.

Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S (2014) Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scan J Infect Dis 46:34–45. https://doi.org/10.3109/00365548.2013.840920 CrossRef

15.

Suzuki A, Uehara Y, Saita M, Inui A isonuma H, Naito T (2016) Raltegravir and abacavir/lamivudine in Japanese treatment-naive and treatment experienced patients with HIV infection: a 48-week retrospective pilot analysis. Jpn J Infect Dis 69:33–38. https://doi.org/10.7883/yoken.JJID.2014.236 CrossRefPubMed

16.

Galli L, Poli A, Muccini C, Galizzi N, Danise A, Spagnuolo V, Gianotti N, Carini E, Lazzarin A, Castagna A (2018) An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. Infect Dis 50(3):220–222. https://doi.org/10.1080/23744235.2017.1374552 CrossRef

17.

Troya J, Montejano R, Ryan P, Gómez C, Matarranz M, Cabello A, Vera F, Sepúlveda MA, Santos I, Samperiz G, Bachiller P, Boix V, Barrufet P, Cervero M, Sanz J, Solís J, Yllescas M, Valencia E, GESIDA-8715 Study Group (2018) Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. PLoS One 13(6):e0198768. https://doi.org/10.1371/journal.pone.0198768 CrossRefPubMedPubMedCentral

18.

Brian J, Collier A, Kharasch E, Whittington D, Thummel KE, Unadkat JD (2011) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39(6):1070–1078. https://doi.org/10.1124/dmd.110.037523 CrossRef

19.

Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D (2014) Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 14(7):581–589. https://doi.org/10.1016/S1473-3099(14)70782-0 CrossRefPubMed

20.

Ward D, Grant R (2012) Rilpivirine/tenofovir/emtricitabine fixed-dose combination is an efficacious and well-tolerated “switch” regimen for patients on therapy. J Int AIDS Soc 15(4):S18351. https://doi.org/10.7448/IAS.15.6.18351 CrossRef

21.

Arae H, Tateyama M, Nakamura H, Tasato D, Kami K, Miyagi K, Maeda S, Uehara H, Moromi M, Nakamura K, Fujita J (2016) Evaluation of the lipid concentrations after switching from antiretroviral drug tenofovir disoproxil fumarate/emtricitabine to abacavir sulfate/lamivudine in virologically-suppressed human immunodeficiency virus-infected patients. Intern Med 55(23):3435–3440. https://doi.org/10.2169/internalmedicine.55.7518 CrossRefPubMedPubMedCentral

22.

Fontas E, Van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P, D:A:D Study Group (2004) Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 189:1056–1074. https://doi.org/10.1086/381783 CrossRefPubMed

23.

Krikke M, Tesselaar K, van den Berk GEL, Otto SA, Freriks LH, van Lelyveld SFL, Visseren FJL, Hoepelman AIM, Arends JE (2018) The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients. HIV Clin Trials 19(2):75–83. https://doi.org/10.1080/15284336.2018 CrossRefPubMed

24.

Casado JL, Santiuste C, Vivancos MJ, Monsalvo M, Moreno A, Perez-Elías MJ, Del Rey JM, Moreno S (2018) Switching to abacavir versus use of a nucleoside-sparing dual regimen for HIV-infected patients with tenofovir-associated renal toxicity. HIV Med. https://doi.org/10.1111/hiv.12630

25.

Cattaneo D, Andreoni M, Carosi G, Cauda R, Lazzarin A, Rizzardini G (2017) Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries? Int J Clin Pharmacol Ther 55(5):381–393. https://doi.org/10.5414/CP202775 CrossRefPubMed

26.

Hill A, Hill T, Jose S, Pozniak A (2014) Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018. J Int AIDS Soc 17(4 Suppl3):19497. https://doi.org/10.7448/IAS.17.4.19497 CrossRefPubMedPubMedCentral

Title: Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
Authors: Jesús Troya
Pablo Ryan
Rocío Montejano
Alfonso Cabello
Guillermo Cuevas
Mariano Matarranz
Irene Cañamares
Javier Solís
Luis Álvarez-Sala Walther
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2019
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-018-3429-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity

Assessment of the tau protein concentration in patients with tick-borne encephalitis

Use of MALDI-TOF mass spectrometry to detect nosocomial outbreaks of Serratia marcescens and Citrobacter freundii

Impact of pre-operative antimicrobial treatment on microbiological findings from endocardial specimens in infective endocarditis

Fourier transform infrared spectroscopy: unlocking fundamentals and prospects for bacterial strain typing

Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page